XOMA Corp
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying XOMA Corp's stock as it has significant potential for growth.
Financial Health
XOMA Corp shows strong revenue and cash flow, indicating good financial stability and performance.
Dividend
XOMA Corp's projected dividend yield of 2.12% offers a modest return for investors seeking dividends. If you invested $1000 you would be paid $21.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring XOMAP
Intellectual Property Royalties
Invest in companies that own the rights to valuable ideas, not just physical products. This collection features businesses earning high-margin income from patents, music catalogs, and character franchises — carefully selected by our analysts to give you exposure to the economics of innovation itself.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical milestone watch
Pipeline trial results and regulatory updates can move the share price; stay aware that outcomes are binary and performance can vary.
Technology platform
A strong platform or novel antibody approach can underpin long-term value, though commercial success is not guaranteed and technical hurdles remain.
Partnership potential
Collaborations or licences can derisk programmes and provide milestones, but terms and counterparties influence ultimate value.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
